NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.72 -0.03 (-3.98%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.70▼$0.7750-Day Range$0.32▼$1.1052-Week Range$0.29▼$1.48Volume3.48 million shsAverage Volume6.04 million shsMarket Capitalization$150.54 millionP/E RatioN/ADividend YieldN/APrice Target$2.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Sangamo Therapeutics alerts: Email Address Sangamo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside268.8% Upside$2.67 Price TargetShort InterestHealthy7.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.47) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector561st out of 910 stocksBiological Products, Except Diagnostic Industry90th out of 155 stocks 3.1 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.73% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 16.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMO. Previous Next 2.2 News and Social Media Coverage News SentimentSangamo Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sangamo Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for SGMO on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 6.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sangamo Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Sangamo Therapeutics Stock (NASDAQ:SGMO)Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.Read More SGMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMO Stock News HeadlinesAugust 30, 2024 | americanbankingnews.comShort Interest in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Decreases By 16.6%August 28, 2024 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 28, 2024 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC WainwrightAugust 28, 2024 | americanbankingnews.comHC Wainwright Weighs in on Sangamo Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:SGMO)August 23, 2024 | markets.businessinsider.comStrong Buy Recommendation for Sangamo Biosciences Amidst Strategic Partnerships and Promising Gene Therapy AdvancementsAugust 19, 2024 | bizjournals.comEast Bay biotech company takes aim at one-in-a-million disease. First it needs millions more in cashAugust 18, 2024 | uk.finance.yahoo.comSangamo Therapeutics, Inc. (0R1D.L)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 9, 2024 | finance.yahoo.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price TargetsAugust 7, 2024 | markets.businessinsider.comSangamo Biosciences: Hold Rating Amid Financial Challenges and Clinical ProgressAugust 7, 2024 | msn.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | finance.yahoo.comSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsAugust 7, 2024 | msn.comWhy Sangamo Therapeutics Stock Is SoaringAugust 6, 2024 | investorplace.comWhy Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?August 6, 2024 | markets.businessinsider.comSangamo Signs Licensing Deal With Genentech To Develop Intravenous Genomic Medicines; Stock UpJuly 24, 2024 | investorplace.comWhy Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?May 29, 2024 | finance.yahoo.comWe Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A MicroscopeSee More Headlines Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Stock Price Target$2.67 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+268.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-257,830,000.00 Net Margins-2,033.69% Pretax Margin-2,024.15% Return on Equity-273.25% Return on Assets-134.24% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$12.28 million Price / Sales12.22 Cash Flow$0.03 per share Price / Cash Flow23.03 Book Value$0.47 per share Price / Book1.54Miscellaneous Outstanding Shares207,510,000Free Float201,700,000Market Cap$150.03 million OptionableOptionable Beta1.23 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Alexander D. Macrae Ch.B (Age 61)M.B., MRCP, Ph.D., CEO, President & Director Comp: $722.67kDr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)Senior VP & Chief Development Officer Comp: $459.9kMs. Amy Pooler Ph.D.Head of ResearchMr. Gregory Davis Ph.D.Head of TechnologyMs. Aron FeingoldHead of Corporate Communications & Investor Relations OfficerMr. Scott B. Willoughby (Age 49)Senior VP, General Counsel & Corporate Secretary Phillip RamseyHead of Technical OperationsMs. Stephanie J. Seiler CLPHead of Business Development & Alliance ManagementMr. David OjalaScientist II - Discovery & Translational ResearchLouise WilkieVice President of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsCellectisNASDAQ:CLLSbluebird bioNASDAQ:BLUEAdaptimmune TherapeuticsNASDAQ:ADAPAtara BiotherapeuticsNASDAQ:ATRALexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 2,898,477 shares on 8/15/2024Ownership: 6.752%Point72 Asia Singapore Pte. Ltd.Bought 247,866 shares on 8/15/2024Ownership: 0.119%Marshall Wace LLPBought 207,476 shares on 8/14/2024Ownership: 0.277%Cubist Systematic Strategies LLCBought 185,813 shares on 8/14/2024Ownership: 0.089%Dimensional Fund Advisors LPSold 34,676 shares on 8/9/2024Ownership: 0.250%View All Insider TransactionsView All Institutional Transactions SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $0.5433 at the beginning of the year. Since then, SGMO shares have increased by 33.1% and is now trading at $0.7230. View the best growth stocks for 2024 here. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative trailing twelve-month return on equity of 273.25%. What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO? 10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees. Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' top institutional shareholders include Armistice Capital LLC (6.75%), Acadian Asset Management LLC (2.20%), Renaissance Technologies LLC (1.99%) and Marshall Wace LLP (0.28%). Insiders that own company stock include Biogen Inc and John Markels. View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD) and Brainstorm Cell Therapeutics (BCLI). This page (NASDAQ:SGMO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
